ArticleThe World Allergy Organization journal2026
Prevalence of allergic diseases and evaluation of total IgE and blood eosinophils as diagnostic biomarkers in Colombia, a tropical country.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The prevalence of allergic conditions and inflammatory T2 diseases has been widely studied in developed countries but less explored in developing countries located in the tropics. Total IgE (tIgE) and blood eosinophils count (BEC) are frequently used for assessing type 2 (T2) inflammation. However, their diagnostic performance information is limited in populations where different non-allergic factors could affect the interpretation of these biomarkers. Objective: To determine the prevalence of asthma, rhinitis, conjunctivitis, rhinosinusitis, and atopic dermatitis, in Colombian population over 18 years old and to evaluate the diagnostic performance of tIgE and BEC. Methods: Cross-sectional national-based study in 6 Colombian cities. The diagnostic performance of the cut-off points for tIgE (100 IU/mL) and BEC (150 cells/uL) suggested by some international guidelines was evaluated with a comparison of allergic group versus non-allergic group. Results: A total of 4248 individuals participated; 1465 (34.4%) had an allergic condition (asthma 13.5%, rhinitis 32.2%, rhinosinusitis 6.3%, conjunctivitis 25.9%, and atopic dermatitis 7.2%). For tIgE, 40.7% of the non-allergic group and 85.9% of the allergic group were over 100 IU/mL (Sensitivity 86%, specificity 59%). For BEC, 43.9% in the non-allergic group and 79.9% in the allergic group were over 150 cells/uL (Sensitivity 79%, specificity 56%). Conclusion: Allergic conditions affect around 30% of the population in Colombia with some differences according with the prevalence of each disease between cities. The cut-off points used traditionally for tIgE and BEC had moderate diagnostic performance to detect allergic diseases in tropical population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.